Lind Global Fund III LP Reduces Stake in Enveric Biosciences (ENVB) to 7.76%

On May 15, 2026, Lind Global Fund III LP filed an amended Schedule 13G (Amendment No. 1) regarding its holdings in Enveric Biosciences, Inc. (ENVB). As of the event date on March 31, 2026, the reporting persons—including Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton—reported beneficial ownership of 158,732 shares of common stock. This represents an ownership percentage of 7.76%, a decrease from the previously reported 9.99%. The reported ownership primarily consists of 79,366 Series G Warrants and 79,366 Series H Warrants. Jeff Easton, as the managing member of the general partner, may be deemed to have sole voting and dispositive power over these securities. The filing includes a standard certification that the securities were not acquired for the purpose of changing or influencing the control of the issuer. The total shares held by Jeff Easton across related entities total 161,232, representing a 7.87% stake in the company.